Navigation Links
Heparin Based Nanoscale Materials Developed For Dialysis Treatment

In what can be called as a breakthrough in the field of nanotechnology, researchers have been successful in engineering nanoscale biomaterials, using heparin//, an anticoagulant. These blood compatible could revolutionize medical treatments, including dialysis, a routine form of treatment for renal failure patients.

Furthermore, these medical devices could have numerous diagnostic and therapeutic applications that are not foreseen at the moment.

The researchers prepared several materials with heparin composites or coatings, including carbon nanotubes, nanofibers, and membranes with nanosized pores, and then demonstrated the materials' high compatibility with blood. Heparin is a common therapeutic used to maintain blood flow or prevent clotting during medical procedures and treatments.

The researchers demonstrated the composite heparin membrane with nanopores could work as an artificial kidney, or dialyzer, by filtering the blood and maintaining its flow. The presence of this blood-compatible dialyzer could potentially eliminate the need for systemic administration of heparin to the patient during kidney dialysis, the researchers say.

The heparin-coated membranes are described in a paper titled ‘Ionic Liquid-Derived Blood Compatible Membranes for Kidney Dialysis,’ published online Apr. 24 in advance of print in the Journal of Biomedical Materials Research.

‘These heparin composite membranes and fibers and coated carbon nanotubes are an enabling technology,’ says Saravanababu Murugesan, a recent doctoral graduate in chemical and biological engineering at Rensselaer and lead author of the paper. ‘Our results show these novel materials have great promise in the development of improved medical devices that are blood compatible.’

The research team is led by Robert Linhardt, the Ann and John H. Broadbent Jr. '59 Senior Constellation Professor of Bio catalysis and Metabolic Engineering at Rensselaer, and includes collaboration with Pulickel Ajayan, the Henry Burlage Professor of Materials Science and Engineering, and Omkaram ‘Om’ Nalamasu, professor of materials science and engineering, at Rensselaer. Additional co-authors of the paper are Shaker Mousa, director of the Pharmaceutical Research Institute at Albany College of Pharmacy, and Aravind Vijayaraghavan, a recent doctoral graduate in materials science and engineering at Rensselaer. Funding for this research was provided by the National Institutes of Health.

Recent results related to this work have been published online in the journals Langmuir (‘Blood Compatible Nanotubes ??? Nano-based Neoproteoglycans,’ Mar. 11, 2006) and Biomacromolecules (‘Preparation of Biopolymer Fibers by Electrospinning from Room Temperature Ionic Liquids,’ Jan. 26, 2006). Provisional patents have been filed by Rensselaer Polytechnic Institute.

Research in Linhardt's group at the Center for Biotechnology and Interdisciplinary Studies at Rensselaer focuses on complex carbohydrates such as heparin. After determining the structure of these molecules, researchers study their biological activities to establish a structure-activity relationship that may reveal lead compounds for new drug development. Recent discoveries include a synthetic method for preparation of heparin in quantities large enough for use in medical treatment.

Source: Euekalert

Related medicine news :

1. Complications In Kidney Failure Patients Linked To Heparin
2. Heparin does not protect from recurrent heart attacks
3. Heparin Antibodies May Put Patients At Risk
4. Ordinary Heparin as Effective as Expensive Blood Thinner
5. Steps To Improve Quality Of Plant-Based Drugs
6. Cancer hazard Found With Animal-Based Nutrients
7. Prime Minister Manmohan Against Incentive-Based Population Control
8. New Oat And Soy-Based Fat Replacer Launched
9. Record Growth Of Soya-Based Dairy Alternatives Over The Past Year In European Markets
10. Race Based Genome Project Launched By Mexico
11. Childhood Asthma Can Be Kept Under Control By Cost-Effective Home Based Interventions
Post Your Comments:

(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/25/2016)... ... June 25, 2016 , ... On Friday, June 10, Van ... Wellness at Work award to iHire in recognition of their exemplary accomplishments in worksite ... 7th annual Maryland Workplace Health & Wellness Symposium at the BWI Marriott in Linthicum ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Those who have ... these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as ... Michigan, has released tools for healthy coping following a traumatic event. , Trauma sufferers ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension Association ... it will receive two significant new grants to support its work to advance ... 25th anniversary by recognizing patients, medical professionals and scientists for their work in ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited ... To Recovery® program to drive cancer patients to and from their cancer treatments. ... highest quality of life and ongoing independence. Getting to and from medical treatments ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... Research and Markets has announced ... Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality ... - Global Forecast to 2021" report to their ... global pharmaceutical excipients market is projected to reach USD ... in the forecast period 2016 to 2021. ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on the ... announced that patient enrollment in its ongoing randomized ... has exceeded 50% of its 24-patient target. Capricor ... the third quarter of 2016, and to report ...
Breaking Medicine Technology: